Your browser doesn't support javascript.
loading
Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy.
Tanizaki, Junko; Kuroda, Hiroaki; Yokoyama, Toshihide; Takahama, Makoto; Shoda, Hiroyasu; Nakamura, Atsushi; Kitamura, Yoshitaka; Mamesaya, Nobuaki; Kadota, Yoshihisa; Sawa, Kenji; Okishio, Kyoichi; Okada, Morihito; Suminaka, Chihiro; Noda, Kenta; Sakai, Kazuko; Chiba, Yasutaka; Nishio, Kazuto; Chamoto, Kenji; Honjo, Tasuku; Yamamoto, Nobuyuki; Nakagawa, Kazuhiko; Hayashi, Hidetoshi.
Afiliação
  • Tanizaki J; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Kuroda H; Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Yokoyama T; Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
  • Takahama M; Department of General Thoracic Surgery, Osaka City General Hospital, Osaka, Japan.
  • Shoda H; Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Nakamura A; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Kitamura Y; Division of Chest Surgery, Hyogo Cancer Center, Akashi, Japan.
  • Mamesaya N; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Kadota Y; Department of General Thoracic Surgery, Osaka Habikino Medical Center, Osaka, Japan.
  • Sawa K; Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Okishio K; Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan.
  • Okada M; Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
  • Suminaka C; Central Research Laboratories, Sysmex Corporation, Hyogo, Japan.
  • Noda K; Central Research Laboratories, Sysmex Corporation, Hyogo, Japan.
  • Sakai K; Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Chiba Y; Clinical Research Center, Kindai University Hospital, Osaka, Japan.
  • Nishio K; Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Chamoto K; Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Honjo T; Department of Immuno-Oncology PDT, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Yamamoto N; Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Nakagawa K; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
  • Hayashi H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
JTO Clin Res Rep ; 4(12): 100590, 2023 Dec.
Article em En | MEDLINE | ID: mdl-38029041
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: JTO Clin Res Rep Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: JTO Clin Res Rep Ano de publicação: 2023 Tipo de documento: Article